Our vast experience in the development of therapeutic agents to combat infectious disease was the primary initiative of our in-house carbapenem drug discovery program and a key factor of its success. To date we have identified two novel carbapenem classes, one class possessing Gram-positive activity and the other possessing Gram-negative activity.
Further advancement of these leads has been successful to the point where they now display potent activity against many of today’s most dangerous drug and multi-drug resistant bacterial strains. Both classes of carbapenem are currently undergoing per-clinical evaluation. In addition, we have successfully completed numerous custom synthesis projects for a variety of pharmaceutical and biotech companies, many of which have been repeat customers. Most recently, we have expanded our internal research capabilities by initiating a biology program to complement and support our drug discovery efforts.